Patient-friendly, non-technical summary of research papers
February 2026 Research Update
This report covers research on Primary hyperoxaluria published in PubMed in February 2026. For other months, see all research updates.
Last update: May 19, 2026
At a glance
Oxalate lowering before transplant (PH1)
One PH1 case report described a large drop in serum oxalate after starting lumasiran before transplant.
Kidney-only transplant outcome (PH1)
In the same report, a kidney-only transplant was followed by stable kidney function reported at 12 months.
Genetic confirmation in PH2
In children with PH2, 17 different GRHPR gene changes were reported (including newly described variants), showing how genetic testing helps confirm the diagnosis.
Faster progression signals in PH2
In one pediatric PH2 cohort, higher starting creatinine and male sex were linked to faster kidney disease progression, but these are group-level signals rather than individual predictions.
Overview
This month, the literature shifted toward more concrete, patient-relevant snapshots of two different situations: transplant planning in primary hyperoxaluria type 1 (PH1) looked more feasible in one closely described case, while primary hyperoxaluria type 2 (PH2) in children appeared more severe and fast-moving in a real-world clinic cohort. The evidence base was uneven, with one report focused on a single person and the other describing outcomes across a pediatric group.
Transplant decisions in PH1 often turn on whether oxalate can be brought down enough to protect a new kidney, and one case report put numbers and timing around that idea. In that person with kidney failure, serum oxalate dropped after starting lumasiran, and a kidney-only transplant followed with stable kidney function reported through 12 months. It is one example, but it makes the sequence of steps and the short-term outcome easier to picture.
In contrast, the pediatric PH2 cohort pointed to a pattern of late recognition and rapid progression. Many children were already at the most advanced stage of chronic kidney disease when first seen, and more reached that stage over the next 24 months. The same report also showed wide variation in changes in the GRHPR gene, including newly described variants, underlining why genetic testing is central to confirming PH2.
The main open questions are how broadly these patterns apply across care settings and what longer-term outcomes look like beyond the time windows reported.
Share
Get the monthly update by email
Subscribe here to receive an email when a new monthly primary hyperoxaluria update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).
Research topics this month
This month brought an early, single-patient report suggesting that lowering oxalate with lumasiran may help make kidney transplant alone possible for some people with primary hyperoxaluria type 1 and kidney failure. In this case, oxalate levels dropped after starting lumasiran and the person went on to have a kidney transplant with stable kidney function reported through 12 months. This adds to the picture that controlling oxalate before and after transplant may be important for protecting a new kidney, although the evidence here is still limited to one person.
The report describes a woman who previously lost a transplanted kidney due to oxalate deposition, which can happen when oxalate levels stay high. After starting lumasiran (an RNA-interference medicine designed to reduce liver oxalate production), her serum oxalate fell from 40 to 8 umol/L, and she then received a kidney transplant alone with immediate graft function. At 12 months, her creatinine was 0.82 mg/dL and serum oxalate was reported as under 1.5 umol/L.
For patients and caregivers, this case mainly adds a concrete example of how oxalate-lowering therapy might fit into transplant planning for PH1 with end-stage kidney disease. It does not prove what will happen for most people, but it helps clarify a possible pathway where reducing oxalate first could support a successful kidney transplant and protect the new kidney over time. What remains uncertain is how often this approach works, which patients benefit most, and what the longer-term outcomes are beyond 12 months.
A pediatric study this month highlighted that many children with primary hyperoxaluria type 2 (PH2) were already in advanced kidney disease by the time they were diagnosed, and many progressed further over 24 months. The report also expanded the catalog of GRHPR gene changes seen in PH2, including several newly described variants. Together, these findings reinforce that PH2 in children can be severe and that genetic testing can clarify the diagnosis and the specific mutation involved.
In a single-center cohort of 52 children in Pakistan with genetically confirmed PH2, 30% were already at chronic kidney disease stage 5 when first seen, and 42% reached stage 5 during the next 24 months. The study reported that male sex and higher baseline creatinine were predictors of progression to stage 5 in this group. It also identified 17 distinct GRHPR mutations, including 6 novel mutations, showing that PH2 genetics can vary widely within one region and clinic population.
For families affected by PH2, this study mainly adds understanding about how the condition may show up and change over time in a real-world pediatric clinic population. It suggests that delayed recognition can coincide with more advanced kidney disease at diagnosis, and it points to baseline kidney function (creatinine) as one marker linked to faster progression in this cohort. These results may matter most for research and for understanding prognosis, because the findings come from one center and may not match patterns in all countries or care settings.
Limitations
The transplant finding in PH1 comes from a single case report, so outcomes for others cannot be inferred.
The PH2 pediatric data came from a single-center cohort, which may not reflect other care settings.
PH2 outcomes were reported over 24 months, leaving longer-term trajectories unclear.
Predictors of PH2 progression (baseline creatinine and male sex) were identified within one cohort and may not generalize.
Important information
This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.
1.Flores K, Merzkani M, Abdulkhalek S, Abuazzam F, Java A, Delos Santos R, Paul R, Gaut J, Alhamad T. A Case of Successful Kidney Transplant-Alone in Primary Hyperoxaluria Type 1 Using Lumasiran. Clin Transplant (2026). Open in new tab
2.Hashmi S, Khatri S, Qaiser H, Abid A, Firasat S, Sultan S, Zubair A, Zafar MN, Ahmed B, Umer SA, Rizvi SAH, Ali I. Clinical burden, genetic heterogeneity, and diagnostic implications in primary hyperoxaluria type 2. Pediatr Nephrol (2026). Open in new tab
